The transthyretin (TTR) amyloid diseases, including Familial Amyloid Polyneuropathy (FAP), are the most common autosomal-dominantly inherited systemic amyloidoses, wherein mutant TTR leads to peripheral and autonomic nervous system degeneration, cardiac dysfunction, or both. The tetrameric TTR protein is primarily secreted by the liver and undergoes dissociation and partial monomer denaturation, followed by extracellular TTR aggregation onto distal postmitotic tissues such as the neurons and heart. However, the mechanism(s) of this cell non-autonomous TTR proteotoxicity have not been elucidated in any model organism. To dissect the mechanism(s) of TTR secretion, degradation, and age-dependent aggregation on TTR cell non-autonomous proteotoxicity, we generated and characterized C. elegans transgenic lines expressing human WT TTR, or the destabilized TTR variants V30M or D18G expressed in the body wall muscle under the
unc-54 promoter. We find that expressing WT TTR and V30M TTR in the muscle significantly reduced the mean lifespan and increased age-dependent paralysis in these strains. To scrutinize TTR toxicity mechanisms, we are using TTR conformational probes (small molecules and antibodies) to monitor the changes in the levels of TTR conformers generated (i.e., tetramer, misfolded oligomers) throughout the lifespan of these strains in order to formulate TTR structure-proteotoxicity relationships. Using a fluorogenic probe that selectively binds and reacts with TTR tetramers, we show that TTR tetramers are secreted from the muscle in WT TTR and V30M TTR strains and are taken up by coelomocytes, six macrophage-like cells in the body cavity where endocytosis and degradation usually takes place. Genetic ablation of coelomocytes appears to increase V30M TTR tetramer levels in the body cavity, suggesting that TTR degradation occurs in these cells. Moreover, coelomocyte ablation significantly exacerbated V30M TTR proteotoxicity resulting in increased sterility and reduced viability, suggesting that modulation of V30M TTR degradation influences its toxicity. Characterization of these models points toward protein degradation as a relevant factor for modulating toxicity in degenerative diseases of postmitotic tissues.